China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 38.53 billion. The enterprise value is 32.89 billion.
| Market Cap | 38.53B |
| Enterprise Value | 32.89B |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 5.93% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +5.93% |
| Shares Change (QoQ) | +20.59% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 16.44% |
| Float | 251.86M |
Valuation Ratios
The trailing PE ratio is 59.86 and the forward PE ratio is 58.76.
| PE Ratio | 59.86 |
| Forward PE | 58.76 |
| PS Ratio | 12.10 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 2.30 |
| P/FCF Ratio | 438.34 |
| P/OCF Ratio | 53.17 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.65, with an EV/FCF ratio of 374.12.
| EV / Earnings | 59.78 |
| EV / Sales | 10.33 |
| EV / EBITDA | 46.65 |
| EV / EBIT | 83.52 |
| EV / FCF | 374.12 |
Financial Position
The company has a current ratio of 6.40, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.40 |
| Quick Ratio | 5.54 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.78 |
| Debt / FCF | 6.31 |
| Interest Coverage | 20.24 |
Financial Efficiency
Return on equity (ROE) is 2.86% and return on invested capital (ROIC) is 1.33%.
| Return on Equity (ROE) | 2.86% |
| Return on Assets (ROA) | 1.19% |
| Return on Invested Capital (ROIC) | 1.33% |
| Return on Capital Employed (ROCE) | 1.84% |
| Revenue Per Employee | 1.81M |
| Profits Per Employee | 311,895 |
| Employee Count | 1,735 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, Cathay Biotech has paid 94.59 million in taxes.
| Income Tax | 94.59M |
| Effective Tax Rate | 15.52% |
Stock Price Statistics
The stock price has increased by +56.95% in the last 52 weeks. The beta is 0.62, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +56.95% |
| 50-Day Moving Average | 50.40 |
| 200-Day Moving Average | 47.48 |
| Relative Strength Index (RSI) | 54.80 |
| Average Volume (20 Days) | 5,583,354 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.18 billion and earned 550.18 million in profits. Earnings per share was 0.89.
| Revenue | 3.18B |
| Gross Profit | 917.58M |
| Operating Income | 402.72M |
| Pretax Income | 609.26M |
| Net Income | 550.18M |
| EBITDA | 713.88M |
| EBIT | 402.72M |
| Earnings Per Share (EPS) | 0.89 |
Balance Sheet
The company has 9.82 billion in cash and 554.98 million in debt, giving a net cash position of 9.27 billion or 12.86 per share.
| Cash & Cash Equivalents | 9.82B |
| Total Debt | 554.98M |
| Net Cash | 9.27B |
| Net Cash Per Share | 12.86 |
| Equity (Book Value) | 21.07B |
| Book Value Per Share | 24.31 |
| Working Capital | 10.14B |
Cash Flow
In the last 12 months, operating cash flow was 724.78 million and capital expenditures -636.88 million, giving a free cash flow of 87.91 million.
| Operating Cash Flow | 724.78M |
| Capital Expenditures | -636.88M |
| Free Cash Flow | 87.91M |
| FCF Per Share | 0.12 |
Margins
Gross margin is 28.81%, with operating and profit margins of 12.65% and 17.28%.
| Gross Margin | 28.81% |
| Operating Margin | 12.65% |
| Pretax Margin | 19.13% |
| Profit Margin | 17.28% |
| EBITDA Margin | 22.42% |
| EBIT Margin | 12.65% |
| FCF Margin | 2.76% |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 0.75%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 0.75% |
| Dividend Growth (YoY) | 110.52% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 25.48% |
| Buyback Yield | -5.93% |
| Shareholder Yield | -5.19% |
| Earnings Yield | 1.43% |
| FCF Yield | 0.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Cathay Biotech has an Altman Z-Score of 6.85 and a Piotroski F-Score of 8.
| Altman Z-Score | 6.85 |
| Piotroski F-Score | 8 |